CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

• Gillison ML MD Anderson Cancer Center, Houston, Texas, USA mgillison@mdanderson.org.
• Blumenschein G MD Anderson Cancer Center, Houston, Texas, USA.
• Fayette J Centre Leon Berard, Lyon, France.
• Guigay J Centre Antoine Lacassagne, FHU OncoAge, Université Côte d'Azur, Nice, France.
• Colevas AD Stanford University, Stanford, California, USA.
• Licitra L Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy.
• Harrington KJ Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, National Institute of Health Research Biomedical Research Centre, London, United Kingdom.
• Kasper S West German Cancer Center, University Hospital, Essen, Germany.
• Vokes EE University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
• Even C Gustave Roussy, Villejuif Cedex, France.
• Worden F University of Michigan, Ann Arbor, Michigan, USA.
• Saba NF Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
• Iglesias Docampo LC Hospital Universitario 12 de Octubre, Madrid, Spain.
• Haddad R Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA.
• Rordorf T Universitätsspital Zurich, Zurich, Switzerland.
• Kiyota N Kobe University Hospital Cancer Center, Kobe, Japan.
• Tahara M National Cancer Center Hospital East, Kashiwa, Japan.
• Monga M Bristol-Myers Squibb, Princeton, New Jersey, USA.
• Lynch M Bristol-Myers Squibb, Princeton, New Jersey, USA.
• Li L Bristol-Myers Squibb, Princeton, New Jersey, USA.
• Ferris RL University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.

Antineoplastic Agents, Immunological

Head and Neck Neoplasms

Humans

Neoplasm Recurrence, Local

Nivolumab

Time Factors